Emerging GLP-1 receptor agonists

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

(2016) R. Keith Campbell et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys

(2011) Emmanuela Gakidou et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

GLP-1 for type 2 diabetes

(2011) Bo Ahrén   EXPERIMENTAL CELL RESEARCH

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus

(2010) D. Joffe   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus

(2010) Lawrence Blonde   AMERICAN JOURNAL OF MEDICINE

Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use

(2010) Sarah L Anderson et al.   ANNALS OF PHARMACOTHERAPY

Response to Comment on: Chauhan et al. (2010) Impact of Common Variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the Risk of Type 2 Diabetes in 5,164 Indians. Diabetes;59:2068-2074

(2010) G. Chauhan et al.   DIABETES

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

(2010) J. B. Buse et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

News and Views

(2010) Iskandar Idris   DIABETES OBESITY & METABOLISM

Global healthcare expenditure on diabetes for 2010 and 2030

(2010) Ping Zhang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

(2010) G. Schernthaner et al.   DIABETOLOGIA

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

(2010) Erin L St Onge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

What evidence should guide the use of thiazolidinediones?

(2010) Matthew C. Riddle   Nature Reviews Endocrinology

Diabesity: an overview of a rising epidemic

(2010) Y. M. K. Farag et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

(2009) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

(2009) L. Blonde et al.   DIABETES OBESITY & METABOLISM

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

(2008) Sten Madsbad et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis

(2008) Laurie L. Baggio et al.   GASTROENTEROLOGY

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE